A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Registration Number
- NCT01358877
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 4804
- Non-metastatic operable primary invasive HER2-positive carcinoma of the breast that is histologically confirmed, and adequately excised
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (</=) 1
- Known hormone receptor status (estrogen receptor and progesterone receptor)
- The interval between definitive surgery for breast cancer and the first dose of chemotherapy must be no more than 8 weeks (56 days). The first cycle of chemotherapy must be administered within 7 days of randomization or on Day 56, whichever occurs first
- Baseline left ventricular ejection fraction (LVEF) greater than or equal to (>/=) 55 percent (%) measured by echocardiogram (ECHO) or Multiple-Gated Acquisition (MUGA) Scan
- Confirmed HER2 positive status
- Completion of all necessary baseline laboratory and radiologic investigations prior to randomization
- Women of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception (as defined by the protocol) by the participant and/or partner for the duration of the study treatment and for at least 7 months after the last dose of study drug
- History of any prior (ipsi- and/or contralateral) invasive breast cancer
- History of non-breast malignancies within the 5 years prior to study entry, except for carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinomas of the skin
- Any "clinical" T4 tumor as defined by primary tumor/regional lymph nodes/distant metastasis (TNM), including inflammatory breast cancer
- Any node-negative tumor
- Any previous systemic chemotherapy for cancer or radiotherapy for cancer
- Prior use of anti-HER2 therapy for any reason or other prior biologic or immunotherapy for cancer
- Concurrent anti-cancer treatment in another investigational trial
- Serious cardiac or cardiovascular disease or condition
- Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness
- Abnormal laboratory tests immediately prior to randomization
- Pregnant or lactating women
- Sensitivity to any of the study medications or any of the ingredients or excipients of these medications
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Pertuzumab + Trastuzumab + Chemotherapy 5-Fluorouracil Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\^2 + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg). Pertuzumab + Trastuzumab + Chemotherapy Carboplatin Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\^2 + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg). Pertuzumab + Trastuzumab + Chemotherapy Cyclophosphamide Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\^2 + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg). Pertuzumab + Trastuzumab + Chemotherapy Docetaxel Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\^2 + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg). Pertuzumab + Trastuzumab + Chemotherapy Doxorubicin Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\^2 + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg). Pertuzumab + Trastuzumab + Chemotherapy Epirubicin Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\^2 + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg). Pertuzumab + Trastuzumab + Chemotherapy Paclitaxel Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\^2 + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg). Pertuzumab + Trastuzumab + Chemotherapy Pertuzumab Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\^2 + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg). Pertuzumab + Trastuzumab + Chemotherapy Trastuzumab Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\^2 + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg). Placebo + Trastuzumab + Chemotherapy 5-Fluorouracil Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram \[mg/kg\] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m\^2) + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin AUC 6 (up to 900 milligrams \[mg\]). Placebo + Trastuzumab + Chemotherapy Carboplatin Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram \[mg/kg\] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m\^2) + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin AUC 6 (up to 900 milligrams \[mg\]). Placebo + Trastuzumab + Chemotherapy Cyclophosphamide Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram \[mg/kg\] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m\^2) + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin AUC 6 (up to 900 milligrams \[mg\]). Placebo + Trastuzumab + Chemotherapy Docetaxel Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram \[mg/kg\] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m\^2) + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin AUC 6 (up to 900 milligrams \[mg\]). Placebo + Trastuzumab + Chemotherapy Doxorubicin Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram \[mg/kg\] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m\^2) + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin AUC 6 (up to 900 milligrams \[mg\]). Placebo + Trastuzumab + Chemotherapy Epirubicin Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram \[mg/kg\] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m\^2) + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin AUC 6 (up to 900 milligrams \[mg\]). Placebo + Trastuzumab + Chemotherapy Paclitaxel Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram \[mg/kg\] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m\^2) + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin AUC 6 (up to 900 milligrams \[mg\]). Placebo + Trastuzumab + Chemotherapy Placebo Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram \[mg/kg\] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m\^2) + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin AUC 6 (up to 900 milligrams \[mg\]). Placebo + Trastuzumab + Chemotherapy Trastuzumab Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram \[mg/kg\] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m\^2) + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin AUC 6 (up to 900 milligrams \[mg\]).
- Primary Outcome Measures
Name Time Method Percentage of Participants With Invasive Disease-Free Survival (IDFS) Event (Excluding Second Primary Non-Breast Cancer [SPNBC]), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings Randomization to the first occurrence of IDFS event (excluding SPNBC) (until data cut-off date 19 December 2016, up to maximum length of follow-up of 59 months) Percentage of participants with IDFS events (excluding SPNBC) is reported. IDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (that is \[i.e.\], an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including ductal carcinoma in situ \[DCIS\] and lobular carcinoma in situ \[LCIS\]) and non-melanoma skin cancer were excluded as an event.
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at Year 3, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings 3 years Kaplan-Meier estimate of the percentage of participants who were IDFS event-free (excluding SPNBC) at Year 3 is reported. IDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including DCIS and LCIS) and non-melanoma skin cancer were excluded as an event.
- Secondary Outcome Measures
Name Time Method Percentage of Participants Who Died Randomization until death due to any cause (until data cut-off date 19 December 2016, up to maximum length of follow-up of 59 months) Percentage of participants who died due to any cause is reported.
Percentage of Participants With IDFS Event (Including SPNBC), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings Randomization to the first occurrence of IDFS event (including SPNBC) (until data cut-off date 19 December 2016, up to maximum length of follow-up of 59 months) Percentage of participants with IDFS events (including SPNBC) is reported. IDFS-SPNBC event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at Year 3, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings 3 years Kaplan-Meier estimate of the percentage of participants who were IDFS event-free (including SPNBC) at Year 3 is reported. IDFS-SPNBC was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).
Percentage of Participants With Disease-Free Survival (DFS) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings Randomization to the first occurrence of DFS event (until data cut-off date 19 December 2016, up to maximum length of follow-up of 59 months) Percentage of participants with DFS event is reported. DFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC or contralateral or ipsilateral DCIS.
Kaplan-Meier Estimate of the Percentage of Participants Who Were DFS Event-Free at Year 3, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings 3 years Kaplan-Meier estimate of the percentage of participants who were DFS event-free at Year 3 is reported. DFS was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC or contralateral or ipsilateral DCIS.
Kaplan-Meier Estimate of the Percentage of Participants Who Were Alive at Year 3 3 years The Kaplan-Meier approach was used to estimate the percentage of participants who were alive at 3 years.
Percentage of Participants With Recurrence-Free Interval (RFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings Randomization until local, regional or distant breast cancer recurrence (until data cut-off date 19 December 2016, up to maximum length of follow-up of 59 months) Percentage of participants with RFI event is reported. RFI event was defined as local, regional or distant breast cancer recurrence.
Kaplan-Meier Estimate of the Percentage of Participants Who Were RFI Event-Free at Year 3, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings 3 years Kaplan-Meier estimate of the percentage of participants who were RFI event-free at Year 3 is reported. RFI event was defined as local, regional or distant breast cancer recurrence.
Percentage of Participants With Distant Recurrence-Free Interval (DRFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings Randomization until distant breast cancer recurrence (until data cut-off date 19 December 2016, up to maximum length of follow-up of 59 months) Percentage of participants with DRFI event is reported. DRFI event was defined as distant breast cancer recurrence.
Kaplan-Meier Estimate of the Percentage of Participants Who Were DRFI Event-Free at Year 3, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings 3 years Kaplan-Meier estimate of the percentage of participants who were DRFI event-free at Year 3 is reported. DRFI event was defined as distant breast cancer recurrence.
Percentage of Participants With Primary Cardiac Event Baseline until data cut-off date 19 December 2016 (up to maximum length of follow-up of 59 months) Primary cardiac event was defined as either: Heart Failure (New York Heart Association \[NYHA\] Class III or IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction (EF) points from baseline and to below 50 percent (%); or cardiac death. Cardiac death was defined as either definite cardiac death: due to heart failure, myocardial infarction, or documented primary arrhythmia; or probable cardiac death: sudden unexpected death within 24 hours of a definite or probable cardiac event (e.g., syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology.
Percentage of Participants With Secondary Cardiac Event Baseline until data cut-off date 19 December 2016 (up to maximum length of follow-up of 59 months) Secondary cardiac event was defined as asymptomatic or mildly symptomatic (NYHA Class II) significant drop in LVEF (defined as an absolute decrease of at least 10 EF points from baseline and to below 50%), confirmed by a second LVEF assessment within approximately three weeks of the first significant LVEF assessment or confirmed by the Cardiac Advisory Board (CAB).
Change From Baseline in LVEF to Worst Post-Baseline Value Baseline until data cut-off date 19 December 2016 (up to maximum length of follow-up of 59 months) LVEF is the fraction of blood (in percent) pumped out of the heart's left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. Baseline LVEF value and the maximum absolute decrease (worst value) in LVEF measurement from baseline were reported. LVEF was measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan.
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Scale Score Baseline, Weeks 13, 25; end of treatment (EOT, 28 days after the last dose, up to Week 56); Follow-up (FU) Months 18, 24, 36 EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall quality of life (QOL) in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting \[N/V\], constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, used 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 global scores were linearly transformed on a scale of 0 to 100, with a high score indicating better GHS/QOL. Negative change from Baseline values indicated deterioration in QOL or functioning and positive values indicated improvement.
Change From Baseline in EORTC QLQ-C30 Functioning Subscale Scores Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36 EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, N/V, constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 functioning scores were linearly transformed on a scale of 0 to 100, with a high score indicating better functioning/support. Negative change from Baseline values indicated deterioration in functioning and positive values indicated improvement.
Percentage of Participants With Response for EQ-5D-3L Questionnaire: Pain/Discomfort Domain Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36 EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in pain/discomfort domain was reported: I have no pain or discomfort; I have moderate pain or discomfort; and I have extreme pain or discomfort. Response percentages may not add up to 100% due to data rounding.
Change From Baseline in EORTC QLQ-C30 Financial Difficulties Subscale Scores Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36 EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, N/V, constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 financial difficulties scores were linearly transformed on a scale of 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicated improvement in financial difficulties and positive values indicated worsening of financial difficulties.
Change From Baseline in EORTC QLQ-C30 Disease/Treatment-Related Symptoms Subscale Scores Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36 EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting \[N/V\], constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 disease/treatment-related symptom scores were linearly transformed on a scale of 0 to 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicated improvement in symptoms and positive values indicated worsening of symptoms.
Change From Baseline in European Organisation for Research and Treatment of Cancer - Breast Cancer Module Quality of Life (EORTC QLQ-BR23) Functional Scale Score Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36 EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \[FP\]) and four symptom scales (systemic side effects \[SE\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for functional scale indicated high/better level of functioning/healthy functioning. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL.
Change From Baseline in EORTC QLQ-BR23 Symptom Scale Score Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36 EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \[FP\]) and four symptom scales (systemic side effects \[SE\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for symptom scale indicated high level of symptomatology/problems/greater degree of symptoms. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL.
Percentage of Participants With Response for European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Mobility Domain Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36 EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in mobility domain was reported: I have no problems in walking about; I have some problems in walking about; and I am confined to bed. Response percentages may not add up to 100% due to data rounding.
Percentage of Participants With Response for EQ-5D-3L Questionnaire: Self-Care Domain Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36 EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in self-care domain was reported: I have no problems with self-care; I have some problems washing or dressing myself; and I am unable to wash or dress myself. Response percentages may not add up to 100% due to data rounding.
Percentage of Participants With Response for EQ-5D-3L Questionnaire: Usual Activities Domain Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36 EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in usual activities domain was reported: I have no problems with performing my usual activities; I have some problems with performing my usual activities; and I am unable to perform my usual activities. Response percentages may not add up to 100% due to data rounding.
Percentage of Participants With Response for EQ-5D-3L Questionnaire: Anxiety/Depression Domain Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36 EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in anxiety/depression domain was reported: I am not anxious or depressed; I am moderately anxious or depressed; and I am extremely anxious or depressed. Response percentages may not add up to 100% due to data rounding.
Trough Serum Concentration (Cmin) of Pertuzumab Cycles 1, 10 and 15 (Cycle length=21 days) Cmin of Trastuzumab Cycles 1, 10 and 15 (Cycle length=21 days) Peak Serum Concentration (Cmax) of Pertuzumab Cycles 1, 10 and 15 (Cycle length=21 days) Cmax of Trastuzumab Cycles 1, 10 and 15 (Cycle length=21 days)
Trial Locations
- Locations (555)
Texas Oncology - DFW
🇺🇸Dallas, Texas, United States
The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc.
🇺🇸Columbus, Ohio, United States
Rush University Medical Center
🇺🇸Chicago, Illinois, United States
Uni of Chicago
🇺🇸Chicago, Illinois, United States
Inst. Nacional de Cancerologia; Clinica de Seno
🇨🇴Bogota, Colombia
Núcleo de Especialidades Oncológicas
🇲🇽Guadalajara, Jalisco, Mexico
University Hospital Limerick - Oncology
🇮🇪Limerick, Ireland
Hospital Angeles Metropolitano; Room 220
🇲🇽Mexico City, Mexico CITY (federal District), Mexico
Instituto Nacional de Enfermedades Neoplasicas
🇵🇪Lima, Peru
Buddhachinaraj Phitsanulok Hospital; Chemotherapy Unit ; Department of Medicine
🇹🇭Phitsanuok, Thailand
Surat Thani Hospital
🇹🇭Surat Thani, Thailand
Massachusetts General Hospital.
🇺🇸Boston, Massachusetts, United States
Dana Farber Cancer Institute at Faulkner Hospital
🇺🇸Boston, Massachusetts, United States
Dana Farber Can Ins
🇺🇸Boston, Massachusetts, United States
Kaiser Permanente - Hayward
🇺🇸Hayward, California, United States
Cedars-Sinai Medical Center
🇺🇸Los Angeles, California, United States
K. Permanente - San Jose
🇺🇸San Jose, California, United States
Hematology Oncology Associates of the Treasure Coast
🇺🇸Port Saint Lucie, Florida, United States
Georgia Cancer Specialists
🇺🇸Atlanta, Georgia, United States
Kaiser Permanente - Roseville
🇺🇸Roseville, California, United States
Illinois Cancer Care
🇺🇸Peoria, Illinois, United States
Rocky Mountain Cancer Center - Denver
🇺🇸Littleton, Colorado, United States
Eastern Ct Hema/Onco Assoc; Dept of Oncology
🇺🇸Norwich, Connecticut, United States
Ocala Oncology Center
🇺🇸Ocala, Florida, United States
K. Permanente - Santa Clara
🇺🇸Santa Clara, California, United States
Florida Cancer Specialists, Research Department
🇺🇸West Palm Beach, Florida, United States
Providence Regional Medical Center
🇺🇸Everett, California, United States
Kootenai Cancer Center
🇺🇸Post Falls, Idaho, United States
K. Permanente - Walnut Creek
🇺🇸Walnut Creek, California, United States
Carolina Oncology Specialists, PA - Hickory
🇺🇸Hickory, North Carolina, United States
Washington Cancer Institute at MedStar Washington Hospital Center.
🇺🇸Washington, District of Columbia, United States
Loyola University Med Center
🇺🇸Maywood, Illinois, United States
Mount Sinai Beth Israel Medical Center
🇺🇸New York, New York, United States
Coborn Cancer Center
🇺🇸Saint Cloud, Minnesota, United States
Roswell Park Cancer Inst.
🇺🇸Buffalo, New York, United States
Dayton Clinical Oncology Prog
🇺🇸Centerville, Ohio, United States
Toledo Clinic Cancer Center
🇺🇸Toledo, Ohio, United States
Tennessee Oncology , PLLC - Chattanooga
🇺🇸Chattanooga, Tennessee, United States
Southdale Cancer Clinic
🇺🇸Edina, Minnesota, United States
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
🇦🇹Salzburg, Austria
Heartland CCOP/Missouri Baptist Medical Center
🇺🇸Saint Louis, Missouri, United States
Isis Centro Especializado de Luces; Oncology
🇦🇷Santa Fe, Argentina
New York Oncology Hematology, P.C.
🇺🇸Albany, New York, United States
Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I
🇦🇹Graz, Austria
Albert Einstein Healthcare Network ; Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Metro-Minnesota Community Oncology Research Consortium
🇺🇸Saint Louis Park, Minnesota, United States
A. Ö. Krankenhaus Der Barmherzigen Brüder; Interne Abt.
🇦🇹St Veit An Der Glan, Austria
Institut Jules Bordet
🇧🇪Anderlecht, Belgium
Sanford USD School of Medicine
🇺🇸Sioux Falls, South Dakota, United States
Bcca - Vancouver Island Cancer Centre; Oncology
🇨🇦Victoria, British Columbia, Canada
Credit Valley Hospital/Carlo Fidani Peel Regional Cancer Centre
🇨🇦Mississauga, Ontario, Canada
Southlake Regional Health Center
🇨🇦Newmarket, Ontario, Canada
CancerCare Manitoba; Neuro-Oncology
🇨🇦Winnipeg, Manitoba, Canada
GHdC Site Notre Dame
🇧🇪Charleroi, Belgium
UZ Leuven Gasthuisberg
🇧🇪Leuven, Belgium
Clinique Ste-Elisabeth
🇧🇪Namur, Belgium
UMHAT Tsaritsa Yoanna - ISUL; Clinic of Oncotherapy
🇧🇬Sofia, Bulgaria
Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie
🇦🇹Wien, Austria
Krankenhaus Der Stadt Wien-Hietzing; Abt. Für Gynäkologie U. Geburtshilfe
🇦🇹Wien, Austria
Hospital Pablo Tobon Uribe
🇨🇴Medellin, Colombia
AZ Groeninge
🇧🇪Kortrijk, Belgium
Sichuan Provincial People's Hospital
🇨🇳Chengdu, China
Tom Baker Cancer Centre; Dept of Medicine
🇨🇦Calgary, Alberta, Canada
Fakultni nemocnice Olomouc; Onkologicka klinika
🇨🇿Olomouc, Czechia
Allan Blair Cancer Centre
🇨🇦Regina, Saskatchewan, Canada
Lkh Vöcklabruck; I. Abt. Für Innere Medizin
🇦🇹Vöcklabruck, Austria
Klinikum Kreuzschwestern Wels; Iii. Interne Abt.
🇦🇹Wels, Austria
BC Cancer ? Surrey
🇨🇦Surrey, British Columbia, Canada
BCCA-Vancouver Cancer Centre
🇨🇦Vancouver, British Columbia, Canada
UZ Antwerpen
🇧🇪Edegem, Belgium
Jessa Zkh (Campus Virga Jesse)
🇧🇪Hasselt, Belgium
CHU Sart-Tilman
🇧🇪Liège, Belgium
Fujian Medical University Union Hospital
🇨🇳Fuzhou City, China
The First Affiliated Hospital of College of Medicine, Zhejiang University
🇨🇳Hangzhou, China
MULTISCAN, s.r.o., Radiologicke centrum Pardubice
🇨🇿Pardubice, Czechia
Hopital Sacre-Coeur Research Centre
🇨🇦Montreal, Quebec, Canada
Masarykuv onkologicky ustav
🇨🇿Brno, Czechia
Atlantic Health Science Corporation; Saint John Regional Hospital Facility
🇨🇦Saint John, New Brunswick, Canada
London Health Sciences Centre
🇨🇦London, Ontario, Canada
BC Cancer Agency, CSI
🇨🇦Kelowna, British Columbia, Canada
Hopital Maisonneuve- Rosemont; Oncology
🇨🇦Montreal, Quebec, Canada
Northeastern Ontario; Regional Cancer Centre
🇨🇦Sudbury, Ontario, Canada
Fundacion Arturo Lopez Perez
🇨🇱Santiago, Chile
the First Hospital of Jilin University
🇨🇳Changchun, China
Jilin Cancer Hospital
🇨🇳Changchun, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, China
ICL; Hematologie
🇫🇷Saint-Priest en Jarez, France
Onkologische Schwerpunktpraxis Bielefeld; Haemotologie & Internistische onkologie
🇩🇪Bielefeld, Germany
Centre Oscar Lambret; Cancerologie Gynecologique
🇫🇷Lille, France
Hochwaldkrankenhaus
🇩🇪Bad Nauheim, Germany
Gesundheitszentrum St. Marien GmbH; Med. II, Hämatologie/Onkologie
🇩🇪Amberg, Germany
Oncomedica S.A.
🇨🇴Monteria, Colombia
Fundacion Cardioinfantil
🇨🇴Bogota, Colombia
Uni Hospital Split; Oncology & Radiotherapy
🇭🇷Split, Croatia
Shanghai First People's Hospital
🇨🇳Shanghai, China
Institut Sainte Catherine
🇫🇷Avignon, France
Institut Bergonie; Oncologie
🇫🇷Bordeaux, France
Clinical Hospital Centre Zagreb
🇭🇷Zagreb, Croatia
Hospital Diagnostico Escalón
🇸🇻San Salvador, El Salvador
Institut Daniel Hollard
🇫🇷Grenoble, France
Clinique des Ormeaux; Oncologie
🇫🇷Le Havre, France
Centre Georges-François Lecler; Ctr de Lutte Contre le Canc
🇫🇷Dijon, France
Hospital Oncologia; Oncology
🇸🇻Salvador, El Salvador
Hopital Dupuytren; Oncologie Medicale
🇫🇷Limoges, France
Centre Jean Perrin; Hopital De Jour
🇫🇷Clermont Ferrand, France
ICONE
🇫🇷Bezannes, France
Centre Francois Baclesse; Recherche Clinique
🇫🇷Caen, France
Universitätsklinikum "Carl Gustav Carus"; Frauenheilkunde und Geburtshilfe
🇩🇪Dresden, Germany
Klinikum der Universität München; Frauenklinik - Onkologie II
🇩🇪München, Germany
Bács-Kiskun Vármegyei Oktatókórház
🇭🇺Kecskemet, Hungary
Clinica El Golf
🇵🇪San Isidro, Peru
Clinica Peruana Americana
🇵🇪Trujillo, Peru
Rizal Medical Center
🇵🇭Pasig City, Philippines
Centrum Onkologii;Im. Franciszka Lukaszczyka;Onkologii
🇵🇱Bydgoszcz, Poland
Opolskie Centrum Onkologii;Oddzial Onkologii Klinicznej
🇵🇱Opole, Poland
NZOZ Mazowiecki Szpital Onkologiczny Uczelni Warszawskiej im. M. Sk?odowskiej-Curie
🇵🇱Wieliszew, Poland
Ospedale Antonio Perrino; Oncologia Medica
🇮🇹Brindisi, Puglia, Italy
Clinica Anglo Americana - Centro de Investigacion Oncologia CAA
🇵🇪Lima, Peru
University Of Santo Tomas; Oncology; Benavides Cancer Institute
🇵🇭Manila, Philippines
S.I. Russian Oncological Research Center n.a. N.N. Blokhin
🇷🇺Moscow, Moskovskaja Oblast, Russian Federation
Prof. Dr. I. Chiricuta Institute of Oncology
🇷🇴Cluj Napoca, Romania
Oncology Inst. Cluj-Napoca; Cancer Dept
🇷🇴Cluj-Napoca, Romania
Institute of Oncology Ljubljana
🇸🇮Ljubljana, Slovenia
SBI of Healthcare Samara Regional Clinical Oncology Dispensary
🇷🇺Samara, Russian Federation
Hospital Juan Ramon Jimenez;Servicio de Oncologia
🇪🇸Huelva, Spain
Hospital General Universitario J.M Morales Meseguer; Servicio de Oncologia
🇪🇸Murcia, Spain
Veterans Memorial Medical Ctr; Cancer Research Centre
🇵🇭Quezon City, Philippines
Bialostockie Ctr Onkologii; Oddzial Chemioterapii Dziennej
🇵🇱Bialystok, Poland
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
🇵🇱Gdansk, Poland
Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr
🇵🇱Warszawa, Poland
Uni Hospital Linkoeping; Dept. of Oncology
🇸🇪Linköping, Sweden
The Panama Clinic
🇵🇦Panama, Panama
Emergency University Bucharest Hospital; Oncology Department
🇷🇴Bucharest, Romania
SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary
🇷🇺Stavropol, Russian Federation
Centro Oncologico MD Anderson Internacional; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario Clínico San Carlos; Servicio de Oncologia
🇪🇸Madrid, Spain
Euroclinic Center of Oncology SRL
🇷🇴Iasi, Romania
Luzerner Kantonsspital; Medizinische Onkologie
🇨🇭Luzern, Switzerland
Hospital Universitario Virgen del Rocio; Servicio de Oncologia
🇪🇸Sevilla, Spain
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
🇪🇸Valencia, Spain
Karolinska University Hospital; Department of General Oncology
🇸🇪Stockholm, Sweden
Royal Berkshire Hospital; Berkshire Cancer Centre
🇬🇧Berkshire, United Kingdom
Lvov State Regional Oncology Medical & Diagnostic Center
🇺🇦Lvov, Ukraine
Tula Regional Oncology Dispensary
🇷🇺Tula, Russian Federation
Hospital Univ. Nuestra Señora de Valme; Servicio de Oncologia
🇪🇸Sevilla, Spain
VETERANS GENERAL HOSPITAL; Department of General Surgery
🇨🇳Taipei, Taiwan
Brust-Zentrum Zürich AG Seefeldstrasse 214 Zürich
🇨🇭Zürich, Switzerland
National Cheng Kung Uni Hospital; Surgery
🇨🇳Tainan, Taiwan
National Taiwan Uni Hospital; General Surgery
🇨🇳Taipei, Taiwan
Instituto Valenciano Oncologia; Oncologia Medica
🇪🇸Valencia, Spain
Ivano-Frankivsk Regional Oncology Center
🇺🇦Ivano-Frankivsk, Ukraine
Norrlands Universitetssjukhus, Umeå, Cancercentrum; Dept of Oncology
🇸🇪Umea, Sweden
Akademiska sjukhuset, Onkologkliniken
🇸🇪Uppsala, Sweden
Hospital Ramon y Cajal; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario 12 de Octubre; Servicio de Oncologia
🇪🇸Madrid, Spain
Lopburi Cancer Hospital; Chemotherpy Unit; Chemotherapy
🇹🇭Lopburi, Thailand
State Medical Academy; Oncology
🇺🇦Dnipropetrovsk, Ukraine
Universitaetsspital Basel; Onkologie
🇨🇭Basel, Switzerland
Taichung Veterans General Hospital; Dept of Surgery
🇨🇳Taichung, Taiwan
Cherkassy Regional Oncological Hospital
🇺🇦Cherkassy, Ukraine
Kyiv City Clinical Oncological Center, Day Hospital Department for Oncological patients
🇺🇦Kiev, Ukraine
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
🇪🇸Madrid, Spain
Cheltenham General Hospital; Gloucestershire Oncology Centre
🇬🇧Cheltenham, United Kingdom
Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica
🇪🇸Madrid, Spain
IInstituto Oncologico de San Sebastian, Oncologikoa; Servicio de Oncologia
🇪🇸San Sebastian, Guipuzcoa, Spain
Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia
🇪🇸Toledo, Spain
Velindre Cancer Centre; Oncology Dept
🇬🇧Cardiff, United Kingdom
Ternopil State Medical Academy
🇺🇦Ternopil, Ukraine
Churchill Hospital; Oxford Cancer and Haematology Centre
🇬🇧Oxford, United Kingdom
Hospital Clinico Universitario de Salamanca; Servicio de Oncologia
🇪🇸Salamanca, Spain
New Cross Hospital; Deansley Centre
🇬🇧Wolverhampton, United Kingdom
Changhua Christian Hospital; Dept of Surgery
🇨🇳Changhua, Taiwan
Kaohsiung Medical Uni Chung-Ho Hospital; Dept of Surgery
🇨🇳Kaohsiung, Taiwan
Chiang Rai Prachanukraw Hospital; Department of Pediatrics, Faculty of Medicine
🇹🇭Chiang Rai, Thailand
Songklanagarind Hospital; Department of Surgery
🇹🇭Songkla, Thailand
Volyn Regional Oncology Dispensary
🇺🇦Lutsk, Ukraine
Tri-Service General Hospital, Division of General Surgery
🇨🇳Taipei, Taiwan
Mount Vernon Hospital; Centre For Cancer Treatment
🇬🇧Northwood, United Kingdom
St James Uni Hospital; Icrf Cancer Medicine Research Unit
🇬🇧Leeds, United Kingdom
The Clatterbridge Cancer Ctr For Oncolgy
🇬🇧Wirral, United Kingdom
Nottingham City Hospital; Oncology
🇬🇧Nottingham, United Kingdom
Weston Park Hospital; Cancer Clinical Trials Centre
🇬🇧Sheffield, United Kingdom
Southern California Kaiser Permanente
🇺🇸San Diego, California, United States
Texas Oncology - Houston (Gessner)
🇺🇸Houston, Texas, United States
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica
🇮🇹Perugia, Umbria, Italy
Fundacion Rodolfo Padilla Padilla A.C.
🇲🇽León, Guanajuato, Mexico
Boston Medical Center
🇺🇸Boston, Massachusetts, United States
K. Permanente - San Fransisco
🇺🇸San Francisco, California, United States
Vanderbilt Breast Center at One Hundred Oaks
🇺🇸Nashville, Tennessee, United States
Tennessee Oncology - Nashville
🇺🇸Nashville, Tennessee, United States
Aalborg Universitetshospital; Onkologisk Afdeling
🇩🇰Aalborg, Denmark
Sydvestjysk Sygehus Esbjerg; Onkologisk afdeling
🇩🇰Esbjerg, Denmark
Herlev Hospital; Afdeling for Kræftbehandling
🇩🇰Herlev, Denmark
Nordsjællands Hospital, Hillerød, Onkologisk Afdeling
🇩🇰Hillerod, Denmark
Rigshospitalet; Onkologisk Klinik
🇩🇰København Ø, Denmark
Sjællands Universitetshospital, Næstved; Onkologisk Afdeling
🇩🇰Naestved, Denmark
Odense Universitetshospital, Onkologisk Afdeling R
🇩🇰Odense C, Denmark
Sygehus Syd Roskilde; Onkologisk/haematologisk ambulatorium
🇩🇰Roskilde, Denmark
Vejle Sygehus; Onkologisk Afdeling
🇩🇰Vejle, Denmark
The 900th Hospital of PLA joint service support force
🇨🇳Fuzhou, China
The 1st Affiliated Hospital of Nanchang Unversity
🇨🇳Nanchang, China
Ist. Uni Federico Ii; Divisione Di Oncologia Medica - Dpt. Di Medicina Interna
🇮🇹Napoli, Campania, Italy
Ospedale Ramazzini
🇮🇹Carpi, Emilia-Romagna, Italy
Royal Devon & Exeter Hospital; Oncology Centre
🇬🇧Exeter, United Kingdom
Colchester General Hospital
🇬🇧Colchester, Essex, United Kingdom
Royal Cornwall Hospital; Dept of Clinical Oncology
🇬🇧Cornwall, United Kingdom
University Hospital coventry; Oncology Department
🇬🇧Coventry, United Kingdom
Western General Hospital; Edinburgh Breast Unit
🇬🇧Edinburgh, United Kingdom
Ipswich Hospital; Oncology Pharmacy
🇬🇧Ipswich, United Kingdom
St. Bartholomew'S Hospital; Dept of Medical Oncology
🇬🇧London, United Kingdom
Peterborough City Hospital, Edith Cavell Campus; Oncology Department
🇬🇧Peterborough, United Kingdom
UCL Hospital NHS Trust
🇬🇧London, United Kingdom
Uni Hospital of North Staffordshire; Staffordshire Oncology Centre
🇬🇧Stoke-on-Trent, United Kingdom
Polyclinique Bordeaux Nord
🇫🇷Bordeaux, France
Centre Antoine Lacassagne; Hopital De Jour A2
🇫🇷Nice, France
Centre Leonard De Vinci;Chimiotherapie
🇫🇷Dechy, France
Centre Hospitalier Departemental Les Oudairies
🇫🇷La Roche Sur Yon, France
Niagara Health Systems - St. Catherines General Site; Niagara Health System-St. Catharines Site
🇨🇦St. Catharines, Ontario, Canada
Hamilton Health Sciences - Juravinski Cancer Centre
🇨🇦Hamilton, Ontario, Canada
Cancer Centre of Southeastern Ontario; Kingston General Hospital
🇨🇦Kingston, Ontario, Canada
Mount Sinai Hospital
🇨🇦Toronto, Ontario, Canada
Princess Margaret Cancer Center
🇨🇦Toronto, Ontario, Canada
Chum Hopital Notre Dame; Centre D'Oncologie
🇨🇦Montreal, Quebec, Canada
Hopital du Saint Sacrement
🇨🇦Quebec City, Quebec, Canada
Kyoto University Hospital; Breast Surgery
🇯🇵Kyoto, Japan
Tokyo Metropolitan; Komagome Hospital, Surgery
🇯🇵Tokyo, Japan
Korea University Anam Hospital; Oncology Haemotology
🇰🇷Seoul, Korea, Republic of
Clinical Oncology Dispensary of Ministry of Health of Tatarstan
🇷🇺Kazan, Tatarstan, Russian Federation
Hospital de Donostia; Servicio de Oncologia Medica
🇪🇸San Sebastian, Guipuzcoa, Spain
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
🇪🇸Malaga, Spain
Hospital Universitario de Canarias;servicio de Oncologia
🇪🇸La Laguna, Tenerife, Spain
Maryland Oncology & Hematology, PA
🇺🇸Bethesda, Maryland, United States
Cancer Alliance of Nebraska
🇺🇸Omaha, Nebraska, United States
Petz Aladar Megyei Oktato Korhaz; Oncoradiologia
🇭🇺Gyor, Hungary
Cross Can Inst
🇨🇦Edmonton, Alberta, Canada
Sunnybrook Odette Cancer Centre
🇨🇦Toronto, Ontario, Canada
Kaiser Permanente Sacramento Medical Center
🇺🇸Sacramento, California, United States
HonorHealth Research Institute ? Bisgrove
🇺🇸Scottsdale, Arizona, United States
Marin Cancer Care Inc
🇺🇸Greenbrae, California, United States
Kaiser Permanente - Oakland
🇺🇸Oakland, California, United States
UCSD Moores Cancer Center
🇺🇸La Jolla, California, United States
Sutter Cancer Center
🇺🇸Sacramento, California, United States
Kaiser Permanente; Oncology Clinical Trials
🇺🇸Vallejo, California, United States
K. Permanente - S. San Fran
🇺🇸South San Francisco, California, United States
Lutheran Hematology &Oncology
🇺🇸Wheat Ridge, Colorado, United States
Georgetown U; Lombardi Comp Can
🇺🇸Washington, District of Columbia, United States
Mayo Clinic-Jacksonville
🇺🇸Jacksonville, Florida, United States
Memorial Cancer Institute
🇺🇸Hollywood, Florida, United States
Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy)
🇺🇸Jacksonville, Florida, United States
Florida Cancer Specialists; SCRI
🇺🇸Fort Myers, Florida, United States
Memorial Breast Cancer Center
🇺🇸Pembroke Pines, Florida, United States
Northwest Georgia Oncology Centers PC - Marietta
🇺🇸Marietta, Georgia, United States
Florida Cancer Specialists; Saint Petersburg
🇺🇸Saint Petersburg, Florida, United States
Phoebe Putney Memorial Hospital
🇺🇸Albany, Georgia, United States
Edward Cancer Center Naperville
🇺🇸Naperville, Illinois, United States
Quincy Medical Group; Canc Ctr at Blessing Hosp
🇺🇸Quincy, Illinois, United States
Ingalls Memorial Hospital
🇺🇸Harvey, Illinois, United States
Cancer Care of Maine
🇺🇸Brewer, Maine, United States
Edward Cancer Center Plainfield
🇺🇸Plainfield, Illinois, United States
Cancer Center of Acadiana at Lafayette General
🇺🇸Lafayette, Louisiana, United States
Carle Foundation
🇺🇸Urbana, Illinois, United States
Cancer Center of Kansas
🇺🇸Wichita, Kansas, United States
New England Cancer Specialists
🇺🇸Scarborough, Maine, United States
Weinberg CA Inst Franklin Sq
🇺🇸Baltimore, Maryland, United States
Mercy Medical Center
🇺🇸Baltimore, Maryland, United States
Beth Israel Deac Med Ctr; East Campus Rsch Pharmacy
🇺🇸Boston, Massachusetts, United States
Berkshire Hematology, Oncology Pc
🇺🇸Pittsfield, Massachusetts, United States
West Michigan Cancer Center
🇺🇸Kalamazoo, Michigan, United States
Grand Rapids Clinical Oncology Program
🇺🇸Grand Rapids, Michigan, United States
Jackson Oncology Associates, PLLC
🇺🇸Jackson, Mississippi, United States
Dartmouth Hitchcock Med Center
🇺🇸Lebanon, New Hampshire, United States
Saint Barnabas Medical Center
🇺🇸Livingston, New Jersey, United States
Abramson Cancer Center; Univ of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Oncology Hematology Care Inc
🇺🇸Cincinnati, Ohio, United States
South Carolina Oncology Associates - SCRI
🇺🇸Columbia, South Carolina, United States
Magee Womens Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
Northwest Cancer Specialists - Portland (NE Hoyt St)
🇺🇸Portland, Oregon, United States
Cancer Centers of the Carolina; Eastside Medical Center
🇺🇸Greenville, South Carolina, United States
Texas Oncology-Medical City Dallas
🇺🇸Dallas, Texas, United States
Texas Oncology - DFW at Dallas Presbyterian Hospital
🇺🇸Dallas, Texas, United States
Texas Oncology - DFW Fort Worth
🇺🇸Fort Worth, Texas, United States
Texas Oncology-El Paso Cancer Treatment Center Grandview
🇺🇸El Paso, Texas, United States
Cancer Care Centers of South Texas-HOAST - San Antonio
🇺🇸New Braunfels, Texas, United States
Texas Oncology - DFW Plano
🇺🇸Plano, Texas, United States
The Center for Cancer and Blood Disorders - Fort Worth
🇺🇸Fort Worth, Texas, United States
Texas Oncology, P.A. - Garland
🇺🇸Garland, Texas, United States
Texas Oncology-Tyler
🇺🇸Irving, Texas, United States
Community Cancer Trials of Utah
🇺🇸Ogden, Utah, United States
Wellmonth Physician Services
🇺🇸Bristol, Virginia, United States
West Virginia University Hospitals Inc
🇺🇸Morgantown, West Virginia, United States
Providence St. Mary Regional Cancer Center
🇺🇸Walla Walla, Washington, United States
Marshfield Clinic
🇺🇸Marshfield, Wisconsin, United States
Green Bay Oncology/St. Mary?s Hospital
🇺🇸Green Bay, Wisconsin, United States
Centro Medico San Roque
🇦🇷San Miguel de Tucuman, Argentina
Lismore Base Hospital; Cancer Care & Haematology Unit
🇦🇺Lismore, New South Wales, Australia
Mater Misericordiae Hospital; Chemotherapy Cottage
🇦🇺Sydney, New South Wales, Australia
Newcastle Mater Misericordiae Hospital; Oncology
🇦🇺Waratah, New South Wales, Australia
Westmead Hospital; Medical Oncology and Pallative Care
🇦🇺Westmead, New South Wales, Australia
Wesley Medical Centre; Clinic For Haematology and Oncology
🇦🇺Auchenflower, Queensland, Australia
Monash Medical Centre; Oncology
🇦🇺Clayton, Victoria, Australia
Royal Adelaide Hospital; Oncology
🇦🇺Adelaide, South Australia, Australia
Mater Hospital; Oncology
🇦🇺Brisbane, Queensland, Australia
Austin Hospital; Medical Oncology
🇦🇺Heidelberg, Victoria, Australia
Geelong Hospital; Andrew Love Cancer Centre
🇦🇺Geelong, Victoria, Australia
Sir Charles Gairdner Hospital; Medical Oncology
🇦🇺Perth, Western Australia, Australia
Peter Maccallum Cancer Institute; Medical Oncology
🇦🇺Melbourne, Victoria, Australia
Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie
🇦🇹Innsbruck, Austria
Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1
🇦🇹Linz, Austria
Lhk Feldkirch; Interne Medizin Abt.
🇦🇹Rankweil, Austria
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie
🇦🇹Wien, Austria
SHATO - Sofia
🇧🇬Sofia, Bulgaria
SHATOD Dr. Marko Antonov Markov-Varna, EOOD
🇧🇬Varna, Bulgaria
Sint Augustinus Wilrijk
🇧🇪Wilrijk, Belgium
Sun Yet-sen University Cancer Center
🇨🇳Guangzhou City, China
Queen Elizabeth II Health Sciences Centre; Oncology
🇨🇦Halifax, Nova Scotia, Canada
The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)
🇨🇳Beijing, China
INTOP
🇨🇱Providencia, Chile
Hu Nan Provincial Cancer Hospital
🇨🇳Changsha, China
Cancer Hospital Chinese Academy of Medical Sciences.
🇨🇳Beijing, China
Guangdong General Hospital
🇨🇳Guangzhou, China
Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)
🇨🇳Shanghai, China
Changhai Hospital of Shanghai
🇨🇳Shanghai, China
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
🇨🇳Wuhan, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai City, China
Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province)
🇨🇳Shijiazhuang, China
Hubei Cancer Hospital
🇨🇳Wuhan, China
Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech
🇨🇳Wuhan, China
Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology
🇨🇿Hradec Kralove, Czechia
Clinique De L Europe; Pmsi
🇫🇷Amiens, France
HOP Prive Arras Les Bonnettes; Chimiotherapie
🇫🇷Arras, France
ICO Paul Papin; Oncologie Medicale.
🇫🇷Angers, France
Hopital Augustin Morvan; Federation De Cancerologie
🇫🇷Brest, France
Centre Leon Berard; Departement Oncologie Medicale
🇫🇷Lyon, France
Ch Pitie Salpetriere; Cmrr Ile De France Salpetriere
🇫🇷Paris, France
Institut Paoli Calmettes; Oncologie Medicale
🇫🇷Marseille, France
Polyclinique De Gentilly; Hemodialyse
🇫🇷Nancy, France
Institut régional du Cancer Montpellier
🇫🇷Montpellier, France
Institut de cancerologie du Gard
🇫🇷Nimes, France
Polyclinique Francheville; MED CHIMIOTHERAPIE RADIOTHERAPIE
🇫🇷Perigueux, France
Institut Curie; Oncologie Medicale
🇫🇷Paris, France
Centre Eugene Marquis; Unite Huguenin
🇫🇷Rennes, France
Clinique Armoricaine Radiologie; Hopital de Jour
🇫🇷Plerin, France
Ico Rene Gauducheau; Oncologie
🇫🇷Saint Herblain, France
Chu De Poitiers; Chu La Miletrie
🇫🇷Poitiers, France
Centre Henri Becquerel; Oncologie Medicale
🇫🇷Rouen, France
Institut Jean Godinot; Hopital De Jour
🇫🇷Reims, France
Centre Rene Huguenin; CONSULT SPECIALISEES
🇫🇷St Cloud, France
Institut d'oncologie de l'Orangerie; Chimiotherapie
🇫🇷Strasbourg, France
Centre Alexis Vautrin; Oncologie Medicale
🇫🇷Vandoeuvre-les-nancy, France
Hopital Hautepierre; Hematologie Oncologie
🇫🇷Strasbourg, France
Institut Claudius Regaud; Departement Oncologie Medicale
🇫🇷Toulouse, France
Clinique Pasteur; Pneumologie
🇫🇷Toulouse, France
Institut Gustave Roussy; Oncologie Medicale
🇫🇷Villejuif, France
Praxisklinik Krebsheilkunde für Frauen / Brustzentrum (Dres. Kittel/Klare)
🇩🇪Berlin, Germany
Frauenarzt-Zentrum Zehlendorf an der Teltower Eiche
🇩🇪Berlin, Germany
HELIOS Klinikum Berlin-Buch; Klinik für Gynäkologie und Geburtshilfe
🇩🇪Berlin, Germany
Evang. Krankenhaus Frauenklinik
🇩🇪Bergisch Gladbach, Germany
Praxis Dr. Schoenegg
🇩🇪Berlin, Germany
Universitätsklinikum Bonn; Zentrum für Geburtshilfe und Frauenheilkunde
🇩🇪Bonn, Germany
Hämato-Onkologie im Medicum/Home
🇩🇪Bremen, Germany
Praxis Dr. Ralf Lorenz
🇩🇪Braunschweig, Germany
DONAU ISAR Klinikum Deggendorf; Frauenklinik
🇩🇪Deggendorf, Germany
Klinikum Sindelfingen-Böblingen; Frauenklinik
🇩🇪Böblingen, Germany
St. Johannes-Hospital
🇩🇪Dortmund, Germany
Klinikum Chemnitz gGmbH; Frauen- und Kinderklinik
🇩🇪Chemnitz, Germany
Universitätsklinikum Düsseldorf; Frauenklinik
🇩🇪Düsseldorf, Germany
Luisenkrankenhaus GmbH & Co. KG., Brustzentrum
🇩🇪Düsseldorf, Germany
Universitätsklinikum Erlangen; Frauenklinik
🇩🇪Erlangen, Germany
Praxis für Hamatologie und Onkologie
🇩🇪Erfurt, Germany
Elisabeth-Krankenhaus Brustzentrum
🇩🇪Kassel, Germany
Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus
🇩🇪Frankfurt am Main, Germany
Städtische Kliniken Frankfurt am Main Höchst
🇩🇪Frankfurt, Germany
Klinikum Esslingen; Klinik für Frauenheilkunde und Geburtshilfe
🇩🇪Esslingen, Germany
Praxis für Interdisziplinäre Onkologie und Hämatologie GbR
🇩🇪Freiburg, Germany
Klinik Johann Wolfgang von Goethe Uni; Klinik für Frauenheilkunde und Geburtshilfe
🇩🇪Frankfurt, Germany
Dres.Jochen Wilke und Harald Wagner
🇩🇪Fürth, Germany
SANA Klinikum Hameln-Pyrmont; Frauenklinik / Brustzentrum
🇩🇪Hameln, Germany
Universitätsklinikum Halle (Saale); Universitätsklinik Und Poliklinik Für Gynäkologie
🇩🇪Halle, Germany
Universitätsklinikum Hamburg-Eppendorf; Frauenklinik
🇩🇪Hamburg, Germany
Universitätsklinikum Greifswald; Klinik für Frauenheilkunde und Brustzentrum
🇩🇪Greifswald, Germany
Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg
🇩🇪Heidelberg, Germany
Diakovere Henriettenstift, Frauenklinik
🇩🇪Hannover, Germany
MVZ Onko Medical GmbH Hannover, Ralf Lohse (Geschäftsführer)
🇩🇪Hannover, Germany
Praxisgemeinschaft; Frauenärzte am Bahnhofsplatz
🇩🇪Hildesheim, Germany
Universitätsklinikum des Saarlandes; Klinik f. Frauenheilkunden und Geburtshilfe
🇩🇪Homburg/Saar, Germany
ViDia Christliche Kliniken Karlsruhe, Vincentius-Diakonissen-Kliniken gAG; Frauenklinik
🇩🇪Karlsruhe, Germany
Klinikum Kassel GmbH; Klinik für Frauenheilkunde und Geburtshilfe
🇩🇪Kassel, Germany
Klinikum Landshut Frauenklinik
🇩🇪Landshut, Germany
UNI-Klinikum Campus Kiel Klinik für Gynäkologie und Geburtshilfe
🇩🇪Kiel, Germany
Uniklinik Köln, Klinik und Poliklinik und Geburtshilfe; Brustzentrum Köln
🇩🇪Köln, Germany
St. Elisabeth Krankenhaus Köln GmbH; Gynäkologie und Geburtshilfe
🇩🇪Koeln, Germany
Sankt Elisabeth Krankenhaus; Gynaekology
🇩🇪Leipzig, Germany
Evangelisches Krankenhaus; Abt. Gynäkologie und Geburtshilfe
🇩🇪Ludwigsfelde, Germany
Universitätsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde
🇩🇪Mainz, Germany
Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Frauenheilkunde und Geburtshilfe
🇩🇪Lübeck, Germany
Klinikum rechts der Isar der TU München; Klinik und Poliklinik für Frauenheilkunde
🇩🇪München, Germany
Rotkreuzklinikum München; Frauenklinik
🇩🇪Muenchen, Germany
Brustzentrum Rhein-Ruhr Servicegesellschaft mbH
🇩🇪Mönchengladbach, Germany
Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe
🇩🇪Offenbach, Germany
Hämatologisch/Onkologische Praxis Prof. Dr. Decker, Studienzentrum
🇩🇪Ravensburg, Germany
Universitätsklinikum Münster; Klinik für Frauenheilkunde und Geburtshilfe
🇩🇪Münster, Germany
Medizinisches Versorgungszentrum am Klinikum Oldenburg GmbH
🇩🇪Oldenburg, Germany
Oncologianova GmbH
🇩🇪Recklinghausen, Germany
RoMed Klinikum Rosenheim; Klinik für Gynäkologie und Geburtshilfe
🇩🇪Rosenheim, Germany
Universitätsfrauen- und Poliklinik am Klinikum Suedstadt
🇩🇪Rostock, Germany
MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken
🇩🇪Stade, Germany
Universitätsklinik Tübingen; Frauenklinik
🇩🇪Tübingen, Germany
Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie
🇩🇪Trier, Germany
Universitätsklinikum Ulm Am Michelsberg; Frauenklinik
🇩🇪Ulm, Germany
Dres. Arnd Nusch Naser Ali-Mohammad Kalhori und Werner Langer
🇩🇪Velbert, Germany
Schwarzwald-Baar Klinikum Klinik für Frauenheilkunde und Geburtshilfe
🇩🇪Villingen-Schwenningen, Germany
Hämatologisch-Onkologische Schwerpunktpraxis Dres. Schlag & Schöttker
🇩🇪Würzburg, Germany
St. Josefs-Hospital Wiesbaden
🇩🇪Wiesbaden, Germany
Marien-Hospital Witten; Frauenklinik Brustzentrum
🇩🇪Witten, Germany
Grupo Angeles
🇬🇹Guatemala City, Guatemala
Centro Oncológico Sixtino / Centro Oncológico SA
🇬🇹Guatemala, Guatemala
Queen Mary Hospital; Surgery
🇭🇰Hong Kong, Hong Kong
Debreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika
🇭🇺Debrecen, Hungary
Semmelweis Egyetem Onkologiai Központ
🇭🇺Budapest, Hungary
Mater Misericordiae Uni Hospital; Oncology
🇮🇪Dublin, Ireland
Beaumont Hospital; Cancer Clinical Trials Unit
🇮🇪Dublin, Ireland
Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly
🇭🇺Budapest, Hungary
Veszprem Megyei Csolnoky; Ferenc Korhaz
🇭🇺Veszprem, Hungary
Magyar Honvedseg Egeszsegugyi Kozpont; Fázis I-es Klinikai Farmakológiai Vizsgálóhely
🇭🇺Budapest, Hungary
Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika
🇭🇺Szeged, Hungary
Békés Megyei Pándy Kálmán Kórház; Onkologiai tanszek
🇭🇺Gyula, Hungary
Cork Uni Hospital; Oncology Dept
🇮🇪Cork, Ireland
St. James Hospital; Oncology
🇮🇪Dublin, Ireland
Rambam Medical Center; Oncology
🇮🇱Haifa, Israel
Campus Universitario S.Venuta; Centro Oncologico T.Campanella
🇮🇹Catanzaro, Calabria, Italy
Galway University Hospital; Clinical Trials Department
🇮🇪Galway, Ireland
Kaplan Medical Center; Oncology Inst.
🇮🇱Rehovot, Israel
Rabin MC; Davidof Center - Oncology Institute
🇮🇱Petach Tikva, Israel
Chaim Sheba Medical Center; Oncology Dept
🇮🇱Ramat Gan, Israel
IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica A
🇮🇹Napoli, Campania, Italy
Sourasky / Ichilov Hospital; Oncology Department
🇮🇱Tel Aviv, Israel
Divisione Onc Med dell'Azienda
🇮🇹Udine, Friuli-Venezia Giulia, Italy
Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica
🇮🇹Aviano, Friuli-Venezia Giulia, Italy
Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
🇮🇹Bologna, Emilia-Romagna, Italy
Arcispedale Santa Maria Nuova; Oncologia
🇮🇹Reggio Emilia, Emilia-Romagna, Italy
Ospedale Belcolle Di Viterbo; Oncologia
🇮🇹Viterbo, Lazio, Italy
Az. Osp. Uni Ria San Martino; Cliniche Uni Rie Convenzionate U.O. Oncologia Medical
🇮🇹Genova, Liguria, Italy
IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A
🇮🇹Genova, Liguria, Italy
Irccs Istituto Europeo Di Oncologia (IEO); Ricerca Di Senologia Medica
🇮🇹Milano, Lombardia, Italy
ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica
🇮🇹Brescia, Lombardia, Italy
ASST DI LECCO; Oncologia Medica
🇮🇹Lecco, Lombardia, Italy
Policlinico di Monza; Istituto di Oncologia
🇮🇹Monza, Lombardia, Italy
IRCCS Fondazione Maugeri; Oncologia Medica I
🇮🇹Pavia, Lombardia, Italy
IRCCS Istituto Clinico Humanitas; Oncologia
🇮🇹Rozzano (MI), Lombardia, Italy
Az. Osp. Di Busto P.O. Di Saronno; U.O. Di Oncologia Medica
🇮🇹Saronno, Lombardia, Italy
Ospedale S. Croce Di Fano; Servizio Oncologia
🇮🇹Fano, Marche, Italy
Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico
🇮🇹Candiolo, Piemonte, Italy
Nuovo Ospedale di Prato S. Stefano - Azienda USL Toscana Centro
🇮🇹Prato, Toscana, Italy
Ospedale Di Bolzano; Dept. Di Oncologia
🇮🇹Bolzano, Trentino-Alto Adige, Italy
Azienda Ospedaliera S. Maria - Terni; Oncologia
🇮🇹Terni, Umbria, Italy
Ospedale Mater Salutis; Dept of Oncology
🇮🇹Legnago, Veneto, Italy
Chiba Cancer Center; Breast Surgical Oncology
🇯🇵Chiba, Japan
Aichi Cancer Center Hospital, Breast Oncology
🇯🇵Aichi, Japan
National Cancer Center Hospital East
🇯🇵Chiba, Japan
Natl Hosp Org Shikoku; Cancer Ctr, Surgery
🇯🇵Ehime, Japan
National Hospital Organization Kyushu Cancer Center;Breast Oncology
🇯🇵Fukuoka, Japan
Iwate Med Univ School of Med; Surgery
🇯🇵Iwate, Japan
Tokai University Hospital, Breast Surgery
🇯🇵Kanagawa, Japan
Gunma University Hospital; Department of Thoracic and Visceral Organ Surgery
🇯🇵Gunma, Japan
Sagara Hospital; Breast Surgery
🇯🇵Kagoshima, Japan
Hiroshima City Hiroshima Citizens Hospital; Breast Surgery
🇯🇵Hiroshima, Japan
St. Marianna University School of Medicine Hospital, Breast and Endocrine Surgery
🇯🇵Kanagawa, Japan
Kumamoto Shinto General Hospital; Breast Cancer Center
🇯🇵Kumamoto, Japan
Niigata Cancer Ctr Hospital; Breast Surgery
🇯🇵Niigata, Japan
Kumamoto City Hospital, Breast and Endocrine Surgery
🇯🇵Kumamoto, Japan
Osaka International Cancer Institute; Breast and Endocrine Surgery
🇯🇵Osaka, Japan
National Hospital Organization Osaka National Hospital; Breast Surgery
🇯🇵Osaka, Japan
Saitama Cancer Center, Breast Oncology
🇯🇵Saitama, Japan
Saitama Medical University International Medical Center; Breast Oncology
🇯🇵Saitama, Japan
Jichi Medical School ; Surgery
🇯🇵Tochigi, Japan
National Cancer Center Hospital; Medical Oncology
🇯🇵Tokyo, Japan
Shizuoka General Hospital; Breast Surgery
🇯🇵Shizuoka, Japan
Shizuoka Cancer Center; Breast Surgery
🇯🇵Shizuoka, Japan
The Cancer Inst. Hosp. of JFCR; Breast Oncology Center
🇯🇵Tokyo, Japan
Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology
🇰🇷Seoul, Korea, Republic of
Yonsei University Severance Hospital; Medical Oncology
🇰🇷Seoul, Korea, Republic of
Tokyo Medical Uni. Hospital; Breast Oncology
🇯🇵Tokyo, Japan
Kyunghee University Hospital; Endocrinology
🇰🇷Seoul, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Korea, Republic of
Samsung Medical Centre; Division of Hematology/Oncology
🇰🇷Seoul, Korea, Republic of
Centro Estatal de Oncología de Campeche
🇲🇽Campehe, Campeche, Mexico
Centro Universitario Contra El Cancer
🇲🇽Monterrey, Nuevo LEON, Mexico
Centro de Diagnóstico y Tratamiento Integral de Mama, Hospital San José Tec de Monterrey
🇲🇽Montrrey, Nuevo LEON, Mexico
Oaxaca Site Management Organization
🇲🇽Oaxaca de Juárez, Oaxaca, Mexico
Centro Estatal De Cancerologia De Durango; Oncology
🇲🇽Durango, Mexico
Medisch Centrum Alkmaar
🇳🇱Alkmaar, Netherlands
Amphia ziekenhuis, locatie langendijk
🇳🇱Breda, Netherlands
Academish Ziekenhuis Maastricht (Azm); Inwendige Geneeskunde
🇳🇱Maastricht, Netherlands
Reinier de Graaf Gasthuis
🇳🇱Delft, Netherlands
Isala Klinieken
🇳🇱Zwolle, Netherlands
Waikato Hospital; Dept of Medical Oncology
🇳🇿Hamilton, New Zealand
Palmerston North Hospital; Regional Cancer Treatment Service
🇳🇿Palmerston North, New Zealand
State Budget Institution of Healthcare of Stavropol region Pyatigorsk Oncology Dispensary
🇷🇺Pyatigorsk, Stavropol, Russian Federation
National Hospital; Oncotherapy Dept
🇿🇦Bloemfontein, South Africa
Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
🇪🇸Badalona, Barcelona, Spain
Wits Donald Gordon Clinical Trial Centre; Medical Oncology
🇿🇦Johannesburg, South Africa
Steve Biko Academic Hospital; Oncology
🇿🇦Pretoria, South Africa
Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
🇪🇸Sabadell, Barcelona, Spain
Hospital Universitario Son Espases
🇪🇸Palma De Mallorca, Islas Baleares, Spain
Hospital Univ Vall d'Hebron; Servicio de Oncologia
🇪🇸Sant Andreu de La Barca, Barcelona, Spain
Hospital Universitario Marques de Valdecilla; Servicio de Oncologia
🇪🇸Santander, Cantabria, Spain
Hospital Provincial de Castellon; Servicio de Oncologia
🇪🇸Castellon de La Plana, Castellon, Spain
Hospital Universitario Reina Sofia; Servicio de Oncologia
🇪🇸Córdoba, Cordoba, Spain
Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
🇪🇸Santiago de Compostela, LA Coruña, Spain
Hospital Son Llatzer; Servicio de Oncologia
🇪🇸Palma de Mallorca, Islas Baleares, Spain
Hospital del Mar; Servicio de Oncologia
🇪🇸Barcelona, Spain
Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia
🇪🇸Barcelona, Spain
Hospital Duran i Reynals; Oncologia
🇪🇸Barcelona, Spain
Hospital Clínic i Provincial; Servicio de Hematología y Oncología
🇪🇸Barcelona, Spain
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia
🇪🇸Jaen, Spain
Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología
🇪🇸La Coruña, Spain
Centro Oncológico Gallego José Antonio Quiroga y Piñeiro, Servicio de Oncologia
🇪🇸La Coruña, Spain
Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia
🇪🇸Lerida, Spain
Hospital Universitario Virgen Macarena; Servicio de Oncologia
🇪🇸Sevilla, Spain
Sahlgrenska Universitetssjukhuset; Onkology
🇸🇪Gothenburg, Sweden
Hospital Universitario Miguel Servet; Servicio Oncologia
🇪🇸Zaragoza, Spain
Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia
🇪🇸Valencia, Spain
Hospital Universitario la Fe; Servicio de Oncologia
🇪🇸Valencia, Spain
Hôpitaux Universit. de Genève Gynécologique - Oncologie; Gynécologie
🇨🇭Genève 14, Switzerland
Christie Hospital; Breast Cancer Research Office
🇬🇧Manchester, United Kingdom
Royal Marsden Hospital; Dept of Med-Onc
🇬🇧London, United Kingdom
Royal Marsden Hosp NHS Fnd; Medicine - Breast Unit
🇬🇧Sutton, United Kingdom
Queen Alexandra Hospital; Haematology and Oncology Centre
🇬🇧Portsmouth, United Kingdom
Royal Preston Hosp; Rosemere Cancer Ctr
🇬🇧Preston, United Kingdom
General Hospital Varazdin
🇭🇷Varazdin, Croatia
Hospital General de México; Unidad de Oncologia
🇲🇽Mexico DF, Mexico CITY (federal District), Mexico
Cancerologia de Queretaro; Oncologia
🇲🇽Queretaro, Queretaro, Queretaro, Mexico
Médicos Especialistas en Cáncer SC
🇲🇽Aguascalientes, Mexico
Centro Regional de Enfermedades Oncológicas, S.A.
🇲🇽San Luis Potosi, Mexico
Centro Oncologico America
🇵🇦Panama, Panama
Hospital General Universitario de Elche; Servicio de Oncologia
🇪🇸Elche, Alicante, Spain
Kantonsspital St. Gallen; Onkologie/Hämatologie
🇨🇭St. Gallen, Switzerland
St Vincent'S Uni Hospital; Medical Oncology
🇮🇪Dublin, Ireland
Ente Ospedaliero Ospedali Galliera; S.C. Oncologia Medica
🇮🇹Genova, Liguria, Italy
Virginia Cancer Institute
🇺🇸Richmond, Virginia, United States
University of North Carolina-Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
University of Missouri-Columbia; Ellis Fischel Cancer Center
🇺🇸Kansas City, Missouri, United States
Roper Bon Secours St. Francis Cancer Center
🇺🇸Charleston, South Carolina, United States
Charleston Oncology, P .A
🇺🇸Charleston, South Carolina, United States
Royal Hobart Hospital; Medical Oncology
🇦🇺Hobart, Tasmania, Australia
AORN'S.G.Moscati; Oncologia
🇮🇹Avellino, Campania, Italy
Ottawa Regional Cancer Centre
🇨🇦Ottawa, Ontario, Canada
Montefiore Medical Center
🇺🇸Bronx, New York, United States
SUNY Upstate Medical University
🇺🇸Syracuse, New York, United States
Mount Sinai Beth Israel Comprehensive Cancer Center
🇺🇸New York, New York, United States
Mount Sinai West
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
University of Iowa
🇺🇸Iowa City, Iowa, United States
Queen Mary Hospital; Dept of Medicine
🇭🇰Hong Kong, Hong Kong